A

new year often means new prices for pharmaceuticals, and several companies have imposed price hikes just shy of 10 percent on numerous drugs, a move that appears designed to avoid withering scrutiny of companies that take double-digit increases.

One notable example is Allergan, which last year attempted to single-handedly staunch criticism of the pharmaceutical industry by issuing a “social contract” in which it promised to avoid “price gouging” and limit price hikes to single-digit percentage increases.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe under ‘the rule of 5’s,’ those increases count as 10 pct? Even the 9.5 percent one? Not that anyone will care of course…..

    • I would have much preferred 9.9999 percent. As any math student knows 9.9999 is a non-zero repeating infinitesimal that will never get to 10. Time for our critics to bone up on their irrationals.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy